Immunotherapy plus chemotherapy before and after surgery for gastroesophageal junction cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial combines an experimental immunotherapy drug with standard chemotherapy before and after surgery for patients with a specific type of stomach-esophagus cancer. The goal is to see if this combination improves outcomes, including shrinking the tumor to make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need to have a confirmed diagnosis of adenocarcinoma at the gastroesophageal junction (where the esophagus meets the stomach) that is HER2-negative and tests positive for a marker called CPS (CPS > 5).
- The cancer must be locally advanced but still considered operable, without having spread to distant organs.
- You cannot have had any prior cancer treatment (like chemotherapy, radiation, or immunotherapy).
- You should be in generally good health, with adequate organ function, and able to perform daily activities (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
This trial tests a new drug (pucotenlimab), which helps your immune system fight cancer, combined with chemotherapy, given before and after surgery for gastroesophageal junction cancer. The goal is to see if this combination can shrink the tumor and improve outcomes for patients with this type of cancer.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
This trial tests a combination of shortened radiation therapy, immunotherapy, and chemotherapy given before surgery for cancer at the junction of the esophagus and stomach. The goal is to see if this approach is safe and improves outcomes.
This trial tests a combination of immunotherapy drugs (sintilimab, chemotherapy, and sometimes ipilimumab) given before surgery to shrink stomach or esophageal junction tumors, then continued after surgery. The goal is to improve survival in patients with resectable (removable) gastric or gastroesophageal junction cancer.
Hear when a new GEJ Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.